CN110606871A - 一种小分子多肽rk12及其应用 - Google Patents
一种小分子多肽rk12及其应用 Download PDFInfo
- Publication number
- CN110606871A CN110606871A CN201910889799.7A CN201910889799A CN110606871A CN 110606871 A CN110606871 A CN 110606871A CN 201910889799 A CN201910889799 A CN 201910889799A CN 110606871 A CN110606871 A CN 110606871A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- small molecule
- acinetobacter baumannii
- molecule polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 32
- 150000003384 small molecules Chemical class 0.000 title claims abstract description 14
- 241000588626 Acinetobacter baumannii Species 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 10
- 208000015181 infectious disease Diseases 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000003385 bacteriostatic effect Effects 0.000 abstract description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 4
- 108010078777 Colistin Proteins 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 4
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108060001132 cathelicidin Proteins 0.000 description 2
- 102000014509 cathelicidin Human genes 0.000 description 2
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 101150002916 ABHD16A gene Proteins 0.000 description 1
- MNBHKGYCLBUIBC-UFYCRDLUSA-N Arg-Phe-Phe Chemical compound C([C@H](NC(=O)[C@H](CCCNC(N)=N)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MNBHKGYCLBUIBC-UFYCRDLUSA-N 0.000 description 1
- WAEWODAAWLGLMK-OYDLWJJNSA-N Arg-Trp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WAEWODAAWLGLMK-OYDLWJJNSA-N 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- NQSFIPWBPXNJII-PMVMPFDFSA-N Lys-Phe-Trp Chemical compound C([C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 NQSFIPWBPXNJII-PMVMPFDFSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- UUIYFDAWNBSWPG-IHPCNDPISA-N Trp-Lys-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N UUIYFDAWNBSWPG-IHPCNDPISA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种小分子多肽RK12，其分子量为1901.30Da、等电点为12.02，其氨基酸序列如SEQ ID:1所示。本发明还公开了一种小分子多肽RK12在制备治疗鲍曼不动杆菌感染药物中的应用。本发明中的多肽RK12分子量小、人工合成方便，对鲍曼不动杆菌的抑菌效果明显。
Description
技术领域
本发明属于生物医学技术领域，具体涉及一种小分子多肽RK12及其在制备抗鲍曼不动杆菌感染药物中的应用。
背景技术
抗菌肽是生物体内经诱导产生的一种具有生物活性的小分子多肽，分子量在1000～7000左右，由10～60个氨基酸残基组成。抗菌肽是当生物受到微生物侵入后机体迅速产生的高效、光谱的抗菌肽类分子，来参与机体的免疫反应。抗菌肽作为机体有效的防御分子是广泛存在的，目前已从微生物、植物、昆虫、节肢动物、两栖动物、哺乳动物甚至人体内鉴定出上千种抗菌肽。抗菌肽抗菌机理复杂，但大多数理论都认为其机制涉及到抗菌肽的阳离子性和疏水性与带负电荷的微生物胞膜的作用，抗菌肽和细菌的细胞膜接触后，引起膜通透性改变，或在细菌细胞膜上形成跨膜的孔洞，最后导致细菌内容物外泄而死亡。因此，抗菌肽在杀灭细菌的速度上要远远高于传统的抗生素，且不像抗生素在低浓度下抑制细菌的生长，抗菌肽对细菌的作用几乎都是致死性的。研究表明：抗菌肽与传统抗生素相比，不易诱导耐药菌株的产生；抗菌谱光，对细菌、真菌、病毒、原虫及癌细胞均有作用。已经在家禽体内发现了3个家族的抗菌肽，包括cathelicidin，liver-expressed antimicrobialpeptide(LEAP)，andβ-defensin。这些抗菌肽对于家禽抵抗细菌性、病毒性疾病具有至关重要的作用，相关这些基因的突变或者缺失对于家禽抗微生物感染的能力将有显著的影响；这些抗菌肽除了具有光谱抗菌活性，同时还有高效的抗真菌、抗病毒、抗原虫和(或)抗肿瘤活性，如Bat5和IMc7能杀灭钩端螺旋体，对白色念珠菌、隐球菌和胞膜病毒和寄生虫都有较好的杀灭作用；一些抗菌肽对疱疹病毒、流感病毒、艾滋病病毒有囊膜病毒有明显的杀伤力；此外，有些抗菌肽同时还具有多种其他的调控功能，如Cathelicidin还具有促进伤口愈合、组织损伤修复、化学趋化作用、促血管生成和抗寄生虫等功能，在调节动物机体免疫上有着重要生物学活性。
发明内容
本发明的目的在于克服现有抗生素长期使用后产生耐药菌技术的缺点，提供一种小分子多肽RK12能治疗临床上耐药的鲍曼不动杆菌；同时RK12具有氨基酸数目少、易合成、生产成本低的特点。
本发明的另一个目的在于提供一种小分子多肽RK12在制备抗鲍曼不动杆菌感染药物中的应用。
本发明的目的通过以下技术方案来实现。
小分子多肽RK12，其特征在于，其分子量为1901.30Da、等电点为12.02，其氨基酸序列如SEQ ID NO.1所示。
作为优选技术方案，所述的小分子多肽RK12采用Fmoc固相合成法制备而成。
上述小分子多肽RK12在制备治疗鲍曼不动杆菌感染药物中的应用。
一种药物组合物，其包含有效成分以及药学上可接受的载体和辅料，其特征在于所述有效成分含有上述RK12多肽。
作为优选技术方案，所述药物组合物的制剂类型为溶液型、胶体溶液型、乳剂型或混悬型。
本发明的有益效果是：
本发明中的多肽RK12为人工合成，具有分子量小、人工合成方便、抑菌效果明显的特点，能够应用于制备抗鲍曼不动杆菌感染药物中，具有较好的市场前景。
附图说明
图1为鲍曼不动杆菌刺激小鼠并采用RK12治疗后主要脏器的载菌量对比图；
图2为RK12治疗后小鼠血液中炎症因子的含量对比图。
具体实施方式
下面结合具体实施方式对本发明做进一步的说明，需要指出的是以下实施方式仅是以例举的形式对本发明所做的解释性说明，但本发明的保护范围并不仅限于此，所有本领域的技术人员以本发明的精神对本发明所做的等效的替换均落入本发明的保护范围。
实施例1
小分子多肽RK12的制备采用Fmoc固相合成法，具体步骤如下。
1.称取树脂0.2g放置于干燥洁净的反应管中，加入适量的N,N-二甲基酰胺(DMF)，活化30分钟，将称取第一氨基酸残基1mmol，DMAP 150mg加入到反应管中，DMF做为溶剂反应3小时；反应完毕后用DMF洗3～6次，加入适当的吡啶和乙酸酐，体积比为1:1，反应30min；反应完毕后DMF洗3～6次；然后用哌啶洗脱氨基酸的保护基团Fmoc，洗脱两次每次15min，再用DMF洗4次，甲醇洗2次。
2.称第二个氨基酸3mmol，HBTU 3mmol于反应管中，加入DIEA 0.5ml，反应40分钟，用DMF洗3～6次，加入哌啶溶液两次洗脱氨基酸的保护基团Fmoc，每次10分钟，再用DMF洗4次，甲醇洗2次。
3.重复第二个步骤直到最后一个氨基酸残基。
4.最后一个氨基酸反应完毕后，用三氟乙酸切割2小时，反应抽滤，得到多肽的三氟乙酸溶液，用乙醚沉淀，离心，再用乙醚洗3～5遍，得到白色固体，经过HPLC脱盐冻干得到多肽样本。
实施例2
小分子多肽RK12的抗菌实验
1.制备鲍曼不动杆菌菌液，37℃恒温培养18h，备用；
2.配制浓度为10mg/ml小分子多肽RK12溶液，将直径为5～7mm的圆形定性滤片消毒烘干后浸入上述不同浓度的小分子多肽RK12溶液中；
3.制备LB培养基，灭菌，备用；
4.溶化LB培养基，冷却至50℃，分别加入鲍曼不动杆菌菌液1ml，轻摇均匀，倒入无菌平皿，轻晃使培养基均匀平铺在平皿上；
5.用消毒过的镊子将滤片整齐、有序的放入冷却的平皿内，盖上陶瓦盖，并做标记，置于37℃恒温培养箱内培养24h；
6.用卡尺测量抑菌圈大小，并比较不同浓度小分子多肽RK12对不同来源的鲍曼不动杆菌(中南大学湘雅医院提供)的作用强度。
表1 小分子多肽RK12对不同来源的鲍曼不动杆菌的抑菌效果
由表1可知，小分子多肽RK12对不同来源的鲍曼不动杆菌的最低抑菌浓度分别为10μg/ml、8.5μg/ml、7.5μg/ml、20μg/ml。
实施例3
小分子多肽RK12在动物模型上的治疗效果
1)模型构建
将鲍曼不动杆菌用LB培养基培养至对数期，之后3000rpm离心5min，用无菌生理盐水洗涤3次，最后用生理盐水重悬，分别配制成1×107CFU/ml的菌悬液，置于4℃冰箱备用。
系统性感染鲍曼不动杆菌小鼠动物模型实验选用雄性昆明小鼠，共分为7组，每组6只，每组注射1×107CFU/ml的鲍曼不动杆菌菌悬液，分组如下：1、生理盐水对照组，RK12(1,2,4mg/kg)和多粘菌素E(0.25,0.5,1mg/kg)治组。在接菌之前首先要构建免疫抑制小鼠模型，构建方法如下：
无菌生理盐水配制20mg/ml的环磷酰胺溶液，每天每只小鼠腹腔注射0.2ml环磷酰胺溶液，连续免疫4d，从免疫结束的第二天开始通过尾静脉注射的方式按照分组设计注射不同剂量的鲍曼不动杆菌，给菌刺激后密切观察小鼠的行为和健康情况，如有小鼠死亡，注意记录小鼠的死亡率。鲍曼不动杆菌注射2h后，通过腹腔注射给予生理盐水，RK12和多粘菌素。
2)实验小鼠主要脏器的载菌量检测
48h后处死小鼠并在无菌条件下取出不同分组小鼠的肝脏、脾脏、肺，取一部分组织器官使用电子天平称重，按照1:3(m/v，器官质量/生理盐水体积)的质量体积比例在无菌组织研磨器中进行研磨，后将组织研磨液用无菌生理盐水进行10倍梯度的稀释，最后吸取50μl稀释后的组织研磨液涂在LB固体平板上，倒置于37℃恒温培养箱中培养18h，进行菌落计数，检测结果见图1。
3)实验小鼠血浆中相关炎症因子的检测
小鼠血浆的制备：摘除小鼠眼球，将血液滴到含有抗凝剂的EP管中，1000rpm离心5min，吸取上清液，转移到无菌离心管中，-20℃冻存备用。
相关炎症因子的检测：本实验检测小鼠血浆中IL-6、IL-10、IL-1β和TNF-α的含量变化，采用ELISA检测的方法，检测结果如图2所示。所有试剂盒由达科为生物技术公司提供。
酶联免疫吸附试验(ELISA)是将已知的抗体或者抗原结合在某种固相载体上，并保持其免疫活性。检测时，将待测标本与酶标抗原或者抗体与固相载体上的抗体或者抗原结合，用洗涤的方法将游离的成分洗掉，然后加入酶的作用底物催化显色，进行定性或定量测定。实验步骤主要参考试剂盒说明书，主要实验步骤如下：
标准品的配制：用抗体稀释液将各细胞因子标准品按梯度稀释到一定的浓度，实验中所用标准品的梯度浓度为1000pg/ml、500pg/ml、250pg/ml、125pg/ml、62.5pg/ml、31.3pg/ml、15.6pg/ml。
加样：将稀释后的细胞因子标准品及小鼠血浆样品加入到检测孔中，注意设置空白对照，每孔加入100μl。
加检测抗体：取50μl稀释后的生物素化一抗抗体工作液加入到检测孔中，盖上封板膜，37℃恒温孵育90min。
洗板：扣去板孔内的液体，每孔加入250μl洗涤液，停留3min后弃去板孔内的液体，在滤纸上将残留的液体拍干，重复4次。
加酶：每孔加入100μl辣根过氧化物酶标记的亲和素，盖上封板膜，37℃恒温孵育30min。
显色：洗涤后每孔加入100μl TMB显色液，37℃避光孵育10～30min。
终止：每孔加入100μl 2M的H2SO4终止液，终止反应。
读板：终止反应10min内检测450nm处吸光度值。
4)检测结果分析
由图1可知，经RK12和多粘菌素E治疗后，小鼠体内个器官的鲍曼不动杆菌的数目均明显下降，表示多肽RK12对小鼠模型具有很好的治疗效果。
由图2可知，在小鼠的正常生理状态下，IL-10的浓度为218pg/ml，经鲍曼不动杆菌感染后IL-10的浓度升高到1500pg/ml。经RK12-1(1,2,4mg/kg)和多粘菌素E(0.25,0.5,1mg/kg)治疗后，IL-10的浓度均出现不同程度的下降，与对照组相比均有明显的差异。TNF-α在生理状态下的浓度为48pg/ml，小鼠经鲍曼不动杆菌感染后TNF-α的含量急剧增加，达到116pg/ml。经RK12(1，2，4mg/kg)和多粘菌素E(0.25,0.5,1mg/kg)治疗后，TNF-α的浓度均出现不同程度的下降，与对照组相比均有明显的差异。以上结果说明了多肽RK12在体内可以通过控制上述四种炎症因子的释放来控制系统性感染鲍曼不动杆菌的小鼠的炎症反应水平，同时也说明了RK12在体内具有很好的抗炎症作用，为RK12作为抗深部真菌感染药物的开发奠定了基础。
序列表
<110> 湖南生达生物科技有限公司
<120> 一种小分子多肽RK12及其应用
<130> 2019
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 12
<212> PRT
<213> 人工序列()
<400> 1
Arg Trp Trp Arg Phe Phe Lys Phe Trp Trp Lys Lys
1 5 10
Claims (5)
1.小分子多肽RK12，其特征在于，其分子量为1901.30Da、等电点为12.02，其氨基酸序列如SEQ ID NO.1所示。
2.如权利要求1所述的小分子多肽RK12，其特征在于其采用Fmoc固相合成法制备而成。
3.一种如权利要求1所述小分子多肽RK12在制备治疗鲍曼不动杆菌感染药物中的应用。
4.一种药物组合物，其包含有效成分以及药学上可接受的载体和辅料，其特征在于所述有效成分含有如权利要求1所述多肽。
5.如权利要求4所述的药物组合物，其特征在于所述药物组合物的制剂类型为溶液型、胶体溶液型、乳剂型或混悬型。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910889799.7A CN110606871B (zh) | 2019-09-20 | 2019-09-20 | 一种小分子多肽rk12及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910889799.7A CN110606871B (zh) | 2019-09-20 | 2019-09-20 | 一种小分子多肽rk12及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110606871A true CN110606871A (zh) | 2019-12-24 |
| CN110606871B CN110606871B (zh) | 2022-10-21 |
Family
ID=68892908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910889799.7A Active CN110606871B (zh) | 2019-09-20 | 2019-09-20 | 一种小分子多肽rk12及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110606871B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209809A (zh) * | 2021-12-24 | 2022-03-22 | 苏州佩德生物医药有限公司 | 一种抗痤疮丙酸杆菌的联合用药物组合物及其应用 |
| CN114209808A (zh) * | 2021-12-24 | 2022-03-22 | 苏州佩德生物医药有限公司 | 一种多肽rk12用于制备治疗痤疮药物的应用 |
| CN116270966A (zh) * | 2023-05-16 | 2023-06-23 | 成都佩德生物医药有限公司 | 多肽rk12作为活性成分的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657543A1 (en) * | 2006-07-10 | 2008-01-17 | Osterreichische Akademie Der Wissenschaften | Antimicrobial peptides |
| CN104072583A (zh) * | 2014-05-10 | 2014-10-01 | 冯小荣 | 能抑制和杀灭多种耐药性细菌的多肽 |
| CN109438559A (zh) * | 2018-09-26 | 2019-03-08 | 中国人民解放军陆军军医大学 | 一种抗多重耐药鲍曼不动杆菌的多肽 |
-
2019
- 2019-09-20 CN CN201910889799.7A patent/CN110606871B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2657543A1 (en) * | 2006-07-10 | 2008-01-17 | Osterreichische Akademie Der Wissenschaften | Antimicrobial peptides |
| CN101528248A (zh) * | 2006-07-10 | 2009-09-09 | 奥地利科学院 | 抗微生物肽 |
| CN104072583A (zh) * | 2014-05-10 | 2014-10-01 | 冯小荣 | 能抑制和杀灭多种耐药性细菌的多肽 |
| CN109438559A (zh) * | 2018-09-26 | 2019-03-08 | 中国人民解放军陆军军医大学 | 一种抗多重耐药鲍曼不动杆菌的多肽 |
Non-Patent Citations (2)
| Title |
|---|
| JIAN PENG等: "Antibacterial mechanism of peptide Cec4 against Acinetobacter baumannii", 《INFECT DRUG RESIST》 * |
| 史鹏伟等: "抗菌肽LL-37对鲍曼不动杆菌生物膜的抑制作用", 《南方医科大学学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114209809A (zh) * | 2021-12-24 | 2022-03-22 | 苏州佩德生物医药有限公司 | 一种抗痤疮丙酸杆菌的联合用药物组合物及其应用 |
| CN114209808A (zh) * | 2021-12-24 | 2022-03-22 | 苏州佩德生物医药有限公司 | 一种多肽rk12用于制备治疗痤疮药物的应用 |
| CN114209808B (zh) * | 2021-12-24 | 2023-08-18 | 成都佩德生物医药有限公司 | 一种多肽rk12用于制备治疗痤疮药物的应用 |
| CN114209809B (zh) * | 2021-12-24 | 2023-09-05 | 成都佩德生物医药有限公司 | 一种抗痤疮丙酸杆菌的联合用药物组合物及其应用 |
| CN116270966A (zh) * | 2023-05-16 | 2023-06-23 | 成都佩德生物医药有限公司 | 多肽rk12作为活性成分的应用 |
| CN116270966B (zh) * | 2023-05-16 | 2023-08-18 | 成都佩德生物医药有限公司 | 多肽rk12作为活性成分的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110606871B (zh) | 2022-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110606871B (zh) | 一种小分子多肽rk12及其应用 | |
| CN110627870B (zh) | 一种小分子多肽rk12及其应用 | |
| JP2018521041A (ja) | 低分子ポリペプチドｚｙ４及びその使用 | |
| CN106543271B (zh) | 抗耐药性感染多肽Cbf-14-2及其用途 | |
| CN107252475B (zh) | 天然宿主防御肽Alligatorin4的应用 | |
| CN107446022B (zh) | 一种可拮抗parp1蛋白rna结合活性的多肽pip-14及其应用 | |
| CN107050430A (zh) | 逆转朗格汉斯细胞免疫抑制的方法 | |
| CN112955460B (zh) | 一种拟穴青蟹抗菌肽Scyreprocin及其应用 | |
| CN110156875B (zh) | 抗菌肽H5-p5及其制备方法和应用 | |
| CN113461777B (zh) | 一种具有抗真菌作用的抗菌肽及其制备方法和应用 | |
| CN112646026B (zh) | 基于乳铁蛋白的仿生抗菌功能多肽及制备方法和应用 | |
| CN111518187B (zh) | 抗菌肽dn6nh2及其应用 | |
| CN117430672A (zh) | 一种新型抗菌肽及其药物组合物 | |
| CN108129560A (zh) | 一种突变蜂毒肽MEL-pep及其应用 | |
| CN113181349B (zh) | 靶向m细胞的多表位口服疫苗及其在包虫疫苗中的应用 | |
| CN115261319A (zh) | 一种多肽诱导扩增的nk细胞及用于细胞治疗的用途 | |
| US10100086B2 (en) | Peptide and uses thereof | |
| CN110051669B (zh) | 1，3，3-三甲基-2-苯并咪唑并吡啶乙烯基吲哚鎓碘化物在制备抗癌药物中的应用 | |
| CN107050463A (zh) | 一种药物及其制备方法和应用 | |
| CN110563814B (zh) | 具有免疫调节作用的多肽及其应用 | |
| CN115850368B (zh) | 一种短链抗菌肽及应用 | |
| CN109223801A (zh) | 一种新的胃癌肿瘤干细胞杀伤剂及其应用 | |
| CN114634553B (zh) | 阳离子肽c9及其应用 | |
| CN106432459A (zh) | 花姬蛙抗菌肽及其基因和在制药中的应用 | |
| CN1210302C (zh) | 特异结合血管内皮生长因子受体kdr的小肽及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Gu Dexin Inventor before: Gu Zhixin |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20210806 Address after: 215002 room 503, 5 / F, building a, No. 108, Yuxin Road, Suzhou Industrial Park, Suzhou area, Suzhou (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province Applicant after: Suzhou Peide biomedical Co.,Ltd. Address before: 410000 ka-621, 7th floor, Yannong complex building, Dongfanghong community, No. 459, lushong Road, high tech Development Zone, Yuelu District, Changsha City, Hunan Province Applicant before: Hunan Shengda Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| CB02 | Change of applicant information |
Address after: 610213 Tianfu international bio City, Chengdu, Sichuan (No. 18, Section 2, bio City Middle Road, Shuangliu District) Applicant after: Chengdu Peide biomedical Co.,Ltd. Address before: 215002 room 503, 5 / F, building a, No. 108, Yuxin Road, Suzhou Industrial Park, Suzhou area, Suzhou (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province Applicant before: Suzhou Peide biomedical Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220921 Address after: Room 1413, Building 7, Xinghu 101 Plaza, No. 1101 Xinghu Avenue, Development Zone, Nantong City, Jiangsu Province, 226000 Applicant after: Peide Biotechnology (Nantong) Co.,Ltd. Address before: 610213 Tianfu international bio City, Chengdu, Sichuan (No. 18, Section 2, bio City Middle Road, Shuangliu District) Applicant before: Chengdu Peide biomedical Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231009 Address after: 610219 Tianfu international biological city, Chengdu, Sichuan (No. 18, Section 2, biological city middle road, Shuangliu District) Patentee after: Chengdu Peide biomedical Co.,Ltd. Address before: Room 1413, Building 7, Xinghu 101 Plaza, No. 1101 Xinghu Avenue, Development Zone, Nantong City, Jiangsu Province, 226000 Patentee before: Peide Biotechnology (Nantong) Co.,Ltd. |